

Developing the 2008 Immunization Schedules for Children and Adolescents

ACIP Working Group
Chair: Julie Morita MD

Presented by Angela Calugar MD, MPH

**Immunization Services Division
National Center for Immunization and
Respiratory Diseases
Centers for Disease Control and Prevention**



Presentation Outline

- ◆ **Feedback from immunization providers on current schedules**
- ◆ **Update on the ACIP work group (WG) activities**
- ◆ **Proposed changes to the immunization schedules-- 2008**

Recommended Immunization S

Vaccine ▼	Age ▶	Birth	1 month	2 month
Hepatitis B ¹		HepB	HepB	
Rotavirus ²				Rot
Diphtheria, Tetanus, Pertussis ³				DTaP
<i>Haemophilus influenzae</i> type b ⁴				Hib
Pneumococcal ⁵				PCV
Inactivated Poliovirus				IPV
Influenza ⁶				
Measles, Mumps, Rubella ⁷				
Varicella ⁸				
Hepatitis A ⁹				
Meningococcal ¹⁰				

This schedule indicates the recommended ages for routine administration of childhood vaccines, as of December 1, 2006, for children aged 0–6 years. Any dose recommended age should be administered at any subsequent visit feasible. Additional vaccines may be licensed and recommended during combination vaccines may be used whenever any components of the combination

1. Hepatitis B vaccine (HepB). (Minimum age: birth)

- Administer monovalent HepB to all newborns before hospital discharge.
- If mother is hepatitis surface antigen (HBsAg)-positive, and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB of birth. Determine the HBsAg status as soon as possible.
- If mother is HBsAg-positive, administer HBIG (no later than age 1 month) and HepB (no later than age 2 months).
- If mother is HBsAg-negative, the birth dose can only be given if physician's order and mother's negative HBsAg labor documented in the infant's medical record.

After the birth dose:

- The HepB series should be completed with either monovalent or combination vaccine containing HepB. The second dose administered at age 1–2 months. The final dose should be administered at age ≥24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of a licensed HepB series, at age 9–18 months (generally well-child visit).

4-month dose:

- It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent vaccine is used for the birth dose, a dose at age 4 months is not necessary.

2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)

- Administer the first dose of the vaccine at age 6–12 weeks. Do not start later than age 12 weeks.
- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

- Administer the final dose in the series by age 32 weeks.

Recommended Immunization Sched

Vaccine ▼	Age ▶	7–10 years
Tetanus, Diphtheria, Pertussis ¹		see footnote 1
Human Papillomavirus ²		see footnote 2
Meningococcal ³		MPSV4
Pneumococcal ⁴		
Influenza ⁵		In
Hepatitis A ⁶		
Hepatitis B ⁷		
Inactivated Poliovirus ⁸		
Measles, Mumps, Rubella ⁹		
Varicella ¹⁰		

This schedule indicates the recommended ages for routine administration of licensed childhood vaccines, as of December 1, 2006, for children aged 7–10 years. Additional information is available at <http://www.cdc.gov/nip/recs/child-s>. Any dose not administered at the recommended age should be administered subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other

1. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum age: 10 years for BOOSTRIX[®] and 11 years for ADACEL[®])

- Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids vaccine (Td) booster dose.

- Adolescents aged 13–18 years who missed the 11–12 year Td/Tdap dose should also receive a single dose of Tdap if they have completed recommended childhood DTP/DTaP vaccination series.

2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)

- Administer the first dose of the HPV vaccine series to females at age 11–12 years.

- Administer the second dose 2 months after the first dose and the third dose 4–6 months after the first dose.

- Administer the HPV vaccine series to females at age 13–18 years previously vaccinated.

3. Meningococcal vaccine. (Minimum age: 11 years for meningococcal polysaccharide vaccine [MCV4]; 2 years for meningococcal conjugate vaccine [MPSV4])

- Administer MCV4 at age 11–12 years and to previously unvaccinated adolescents at high school entry (at approximately age 15 years).

- Administer MCV4 to previously unvaccinated college freshmen living in dormitories; MPSV4 is an acceptable alternative.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See *MMWR* 2005;54(No. RR-7):1–21. Use MPSV4 for children 2–10 years and MCV4 or MPSV4 for older children.

The Recommended Immunization Schedules for Persons Aged 0–18 Years

The American Academy of Pediatrics (<http://www.aap.org>)

SAFE

Catch-up Immunization Schedule

UNITED STATES • 2008

for Persons Aged 4 Months–18 Years Who Start Late or Who Are More Than 1 Month Behind

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age.

CATCH-UP SCHEDULE FOR PERSONS AGED 4 MONTHS–6 YEARS					
Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis B ¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)		
Rotavirus ²	6 wks	4 weeks	4 weeks		
Diphtheria, Tetanus, Pertussis ³	6 wks	4 weeks	4 weeks	6 months	6 months ³
<i>Haemophilus influenzae</i> type b ⁴	6 wks	4 weeks (if first dose administered at age <12 months) 8 weeks (as final dose) (if first dose administered at age 12–14 months) No further doses needed (if first dose administered at age ≥15 months)	4 weeks ⁴ (if current age <12 months) 8 weeks (as final dose) ⁴ (if current age ≥12 months and second dose administered at age <15 months) No further doses needed (if previous dose administered at age ≥15 months)	8 weeks (as final dose) (This dose only necessary for children aged 12 months–5 years who received 3 doses before age 12 months)	
Pneumococcal ⁵	6 wks	4 weeks (if first dose administered at age <12 months and current age <24 months) 8 weeks (as final dose) (if first dose administered at age ≥12 months or current age 24–59 months) No further doses needed (for healthy children if first dose administered at age ≥24 months)	4 weeks (if current age <12 months) 8 weeks (as final dose) (if current age ≥12 months and previous dose administered at age ≥24 months)	8 weeks (as final dose) (This dose only necessary for children aged 12 months–5 years who received 3 doses before age 12 months)	
Inactivated Poliovirus ⁶	6 wks	4 weeks	4 weeks	4 weeks ⁶	
Measles, Mumps, Rubella ⁷	12 mos	4 weeks	4 weeks	4 weeks ⁷	
Varicella ⁸	12 mos	3 months	3 months		
Hepatitis A ⁹	12 mos	6 months			

CATCH-UP SCHEDULE FOR PERSONS AGED 7–18 YEARS					
Tetanus, Diphtheria/Tetanus, Diphtheria, Pertussis ¹	7 yrs ¹⁰	4 weeks	4 weeks (if first dose administered at age <12 months) 6 months (if first dose administered at age ≥12 months)	6 months (if first dose administered at age <12 months)	
Human Papillomavirus ¹¹	9 yrs	4 weeks	12 weeks		
Hepatitis A ⁹	12 mos	6 months			
Hepatitis B ¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)		
Inactivated Poliovirus ⁶	6 wks	4 weeks	4 weeks	4 weeks ⁶	
Measles, Mumps, Rubella ⁷	12 mos	4 weeks	4 weeks		
Varicella ⁸	12 mos	4 weeks (if first dose administered at age ≥13 years) 3 months (if first dose administered at age <13 years)			

1. Hepatitis B vaccine (HepB). (Minimum age: birth)

- Administer the 3-dose series to those who were not previously vaccinated.
- A 2-dose series of Recombivax HB[®] is licensed for children aged 11–15 years.

2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)

- Do not start the series later than age 12 weeks.
- Administer the final dose in the series by age 32 weeks. Do not administer a dose later than age 32 weeks.
- Data on safety and efficacy outside of these age ranges are insufficient.

3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)

- The fifth dose is not necessary if the fourth dose was administered at age ≥4 years.
- DTaP is not indicated for persons aged ≥7 years.

4. *Haemophilus influenzae* type b conjugate vaccine (Hib). (Minimum age: 6 weeks)

- Vaccine is not generally recommended for children aged ≥5 years.
- If current age <12 months and the first 2 doses were PRP-OMP (PedvaxHIB[®] or ComVax[®] [Merck]), the third (and final) dose should be administered at age 12–15 months and at least 8 weeks after the second dose.
- If first dose was administered at age 7–11 months, administer 2 doses separated by 4 weeks plus a booster at age 12–15 months.

5. Pneumococcal conjugate vaccine (PCV). (Minimum age: 6 weeks)

- Vaccine is not generally recommended for children aged ≥5 years.

6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)

- For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if third dose was administered at age ≥4 years.
- If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.

7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)

- The second dose of MMR is recommended routinely at age 4–6 years but may be administered earlier if desired.
- If not previously vaccinated, administer 2 doses of MMR during any visit with ≥4 weeks between the doses.

8. Varicella vaccine. (Minimum age: 12 months)

- The second dose of varicella vaccine is recommended routinely at age 4–6 years but may be administered earlier if desired.
- Do not repeat the second dose in persons aged <13 years if administered ≥28 days after the first dose.

9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)

- HepA is recommended for certain groups of children, including in areas where vaccination programs target older children. See *MMWR* 2006;55(No. RR-7):1–23.

10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum age: 7 years for Td, 10 years for BOOSTRIX[®], and 11 years for ADACEL[™])

- Tdap should be substituted for a single dose of Td in the primary catch-up series or as a booster if age appropriate; use Td for other doses.
- A 5-year interval from the last Td dose is encouraged when Tdap is used as a booster dose. A booster (fourth) dose is needed if any of the previous doses were administered at age <12 months. Refer to ACIP recommendations for further information. See *MMWR* 2006;55(No. RR-3).

11. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)

- Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.

Information about reporting reactions after immunization is available online at <http://www.vaers.hhs.gov> or by telephone via the 24-hour national toll-free information line 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for immunization, is available from the National Center for Immunization and Respiratory Diseases at <http://www.cdc.gov/nip/default.htm> or telephone, 800-CDC-INFO (800-232-4636).

DEPARTMENT OF HEALTH AND HUMAN SERVICES • CENTERS FOR DISEASE CONTROL AND PREVENTION • SAFER • HEALTHIER • PEOPLE

The Recommended Immunization Schedules for Persons Aged 0–18 Years
The American Academy of Pediatrics (<http://www.aap.org>)

1

Feedback: lunch rounds at the NIC and NIP-INFO hot line

- ◆ **Format**
 - Easier to read, convenient to print and use for separate age groups
 - Colors are harmonized with adult schedule
 - Catch-up bars (green) in the routine schedule are confusing
 - Catch-up schedule is always very complex
- ◆ **Content**
 - Clearer
 - References in the footnotes are useful
 - Correct level of details
- ◆ **Suggestions**
 - HepB vaccine birth dose
 - Clarifications for PCV indication
 - More details for children with special medical conditions
 - Options for black& white copier machine
 - Use brand names

Update on the WG activities

- ◆ **Met with the adult immunization schedule workgroup**
 - **Persons with special medical conditions**
 - **Timing of publication of the Immunization schedules**
 - **Experience with qualitative survey, Focus Group Discussion**
- ◆ **Provided feedback for draft immunization schedule for HIV-infected children aged 0-6**

Proposed changes to the immunization schedules-- 2008

- ◆ **New vaccines being considered by FDA**
- ◆ **New indications for existing vaccines**
 - **Flumist vaccine maybe recommended for younger age group for 2007-8 season**
- ◆ **Improving schedules' content, format and presentation**

Recommended Immunization Schedule for Persons Aged 0–6 Years—UNITED STATES • 2008

Vaccine▼	Age►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19–23 months	2–3 years	4–6 years
Hepatitis B ¹	HepB		HepB	<i>see footnote 1</i>		HepB						
Rotavirus ²				Rota	Rota	Rota						
Diphtheria, Tetanus, Pertussis ³				DTaP	DTaP	DTaP		DTaP				DTaP
<i>Haemophilus influenzae</i> type b ⁴				Hib	Hib	<i>Hib</i> ⁴	Hib					
Pneumococcal ⁵				PCV	PCV	PCV	PCV				PCV PPV	
Inactivated Poliovirus				IPV	IPV		IPV					IPV
Influenza ⁶							Influenza (Yearly)					
Measles, Mumps, Rubella ⁷							MMR					MMR
Varicella ⁸							Varicella					Varicella
Hepatitis A ⁹								HepA (2 doses)			HepA Series	
Meningococcal ¹⁰											MPSV4	

Range of recommended ages



Certain high-risk groups

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 0–6 years. Additional information is available at <http://www.cdc.gov/nip/recs/child-schedule.htm>. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and

other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <http://www.vaers>, hhs.gov or by telephone, 800-822-7967.

Recommended Immunization Schedule for Persons Aged 7–18 Years—UNITED STATES • 2008

Vaccine ▼	Age ►	7–10 years	11–12 YEARS	13–14 years	15 years	16–18 years
Tetanus, Diphtheria, Pertussis ¹	<i>see footnote 1</i>		Tdap		Tdap	
Human Papillomavirus ²	<i>see footnote 2</i>		HPV (3 doses)		HPV Series	
Meningococcal ³	MPSV4		MCV4		MCV4	
Pneumococcal ⁴			PPV			
Influenza ⁵			Influenza (Yearly)			
Hepatitis A ⁶			HepA Series			
Hepatitis B ⁷			HepB Series			
Inactivated Poliovirus ⁸			IPV Series			
Measles, Mumps, Rubella ⁹			MMR Series			
Varicella ¹⁰			Varicella Series			



Range of recommended ages



Catch-up immunization



Certain high-risk groups

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 7–18 years. Additional information is available at <http://www.cdc.gov/nip/recs/child-schedule.htm>. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components

of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <http://www.vaers.hhs.gov> or by telephone, **800-822-7967**.

Catch-up Immunization Schedule

for Persons Aged 4 Months–18 Years Who Start Late or Who Are More Than 1 Month Behind

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age.

CATCH-UP SCHEDULE FOR PERSONS AGED 4 MONTHS–6 YEARS					
Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis B ¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)		
Rotavirus ²	6 wks	4 weeks	4 weeks		
Diphtheria, Tetanus, Pertussis ³	6 wks	4 weeks	4 weeks	6 months	6 months ³
<i>Haemophilus influenzae</i> type b ⁴	6 wks	4 weeks if first dose administered at age <12 months 8 weeks (as final dose) if first dose administered at age 12–14 months No further doses needed if first dose administered at age ≥15 months	4 weeks ⁴ if current age <12 months 8 weeks (as final dose) ⁴ if current age ≥12 months and second dose administered at age <15 months No further doses needed if previous dose administered at age ≥15 months	8 weeks (as final dose) This dose only necessary for children aged 12 months–5 years who received 3 doses before age 12 months	
Pneumococcal ⁵	6 wks	4 weeks if first dose administered at age <12 months and current age <24 months 8 weeks (as final dose) if first dose administered at age ≥12 months or current age 24–59 months No further doses needed for healthy children if first dose administered at age ≥24 months	4 weeks if current age <12 months 8 weeks (as final dose) if current age ≥12 months No further doses needed for healthy children if previous dose administered at age ≥24 months	8 weeks (as final dose) This dose only necessary for children aged 12 months–5 years who received 3 doses before age 12 months	
Inactivated Poliovirus ⁶	6 wks	4 weeks	4 weeks	4 weeks ⁶	
Measles, Mumps, Rubella ⁷	12 mos	4 weeks			
Varicella ⁸	12 mos	3 months			
Hepatitis A ⁹	12 mos	6 months			
CATCH-UP SCHEDULE FOR PERSONS AGED 7–18 YEARS					
Tetanus, Diphtheria/ Tetanus, Diphtheria, Pertussis ¹⁰	7 yrs ¹⁰	4 weeks	4 weeks if first dose administered at age <12 months 6 months if first dose administered at age ≥12 months	6 months if first dose administered at age <12 months	
Human Papillomavirus ¹¹	9 yrs	4 weeks	12 weeks		
Hepatitis A ⁹	12 mos	6 months			
Hepatitis B ¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)		
Inactivated Poliovirus ⁶	6 wks	4 weeks	4 weeks	4 weeks ⁶	
Measles, Mumps, Rubella ⁷	12 mos	4 weeks			
Varicella ⁸	12 mos	4 weeks if first dose administered at age ≥13 years 3 months if first dose administered at age <13 years			

FOOTNOTES

1. Hepatitis B vaccine (HepB). (Minimum age: birth)

At birth:

- Administer monovalent HepB to all newborns prior to hospital discharge.
- If mother is HBsAg-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIG (no later than age 1 week).
- If mother is HBsAg-negative, the birth dose can only be delayed with physician's order and mothers' negative HBsAg laboratory report documented in the infant's medical record.

Following the birth dose:

- The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered at age ≥ 24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of 3 or more doses in a licensed HepB series, at age 9–18 months (generally at the next well-child visit).

4-month dose of HepB:

- It is permissible to administer 4 doses of HepB when combination vaccines are given after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.

2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)

- Administer the first dose between 6 and 12 weeks of age. Do not start the series later than age 12 weeks.
- Administer the final dose in the series by 32 weeks of age. Do not administer a dose later than age 32 weeks.
- There are insufficient data on safety and efficacy outside of these age ranges.

3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)

- The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
- Administer the final dose in the series at age 4–6 years.

4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)

- If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
- TriHibit® (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in ≥ 12 months olds.

5. Pneumococcal vaccine. (Minimum age: 6 weeks for Pneumococcal Conjugate Vaccine (PCV); 2 years for Pneumococcal Polysaccharide Vaccine (PPV))

- Administer PCV at ages 24–59 months in certain high risk groups. Administer PPV to certain high risk groups aged ≥ 2 years. See MMWR 2000; 49(RR-9):1-35.

6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine (TIV); 5 years for live, attenuated influenza vaccine (LAIV))

- All children aged 6–59 months and close contacts of all children aged 0–59 months are recommended to receive influenza vaccine.
- Influenza vaccine is recommended annually for children aged ≥ 59 months with certain risk factors, healthcare workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006; 55(RR-10):1-41.
- For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
- Children receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if aged ≥ 3 years.
- Children aged ≤ 9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥ 4 weeks for TIV and > 6 weeks for LAIV).

7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)

- Administer the second dose of MMR at age 4–6 years. MMR may be administered prior to age 4–6 years, provided ≥ 4 weeks have elapsed since the first dose and both doses are administered at age ≥ 12 months.

8. Varicella vaccine. (Minimum age: 12 months)

- Administer the second dose of varicella vaccine at age 4–6 years. Varicella vaccine may be administered prior to age 4–6 years, provided that ≥ 3 months have elapsed since the first dose and both doses are administered at age ≥ 12 months. If second dose was administered ≥ 28 days following the first dose, the second dose does not need to be repeated.

9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)

- HepA is recommended for all children at 1 year of age (i.e., 12–23 months). The 2 doses in the series should be administered at least 6 months apart.
- Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
- HepA is recommended for certain other groups of children including in areas where vaccination programs target older children. See MMWR 2006; 55(RR-7):1-23.

10. Meningococcal polysaccharide vaccine (MPSV-4). (Minimum age: 2 years)

- Administer MPSV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high risk groups. See MMWR 2005; 54 (RR-7):1-21.

Proposed changes to the footnotes, 0-6 years

- ◆ In the footnotes ad: *** For additional details see catch-up immunization schedule.**
- ◆ HepB birth dose wording: “If the mother is HBsAg-negative, the birth dose can be delayed, **in rare cases**, with physician’s order and **a copy of the mother’s negative HBsAg laboratory report** in the infant’s medical record.”
- ◆ PCV wording: “Administer PCV at ages 24-59 months in certain high-risk groups; **consider catch-up for other children aged 24-59 months**”

Proposed changes to the footnotes, 7-18 years

◆ In the footnotes ad:

- * **The catch-up bars highlight the importance of the adolescent platform; for additional details see catch-up immunization schedule.**

Proposed changes to the footnotes, catch-up schedule

- ◆ **PCV wording: “Administer PCV at ages 24-59 months in certain high-risk groups; consider catch-up for other children aged 24-59 months. Vaccine is not generally recommended for children aged ≥ 5 years.”**

Summary

- ◆ **Updating immunization schedules requires multiple activities**
 - **Feedback from immunization providers is important**
 - **Collaboration with different ACIP WG-s and subject matter experts**
 - **Harmonization with other stakeholders**
- ◆ **New drafts of the immunization schedules will be presented for the ACIP approval in October, publication January 2007**

Acknowledgments: ACIP WG members and CDC staff

**Curtis Allen
Norman Baylor
Jeffery Berg
Angela Calugar
Susie Childrey
Steve Gordon
Andrew Kroger
Susan Lett
Eric Mast
Lynne McIntyre**

**Nancy Messonnier
Amy Middleman
Julie Morita
Pekka Nuorti
Diane Peterson
Joni Reynolds
Lorry Rubin
Patsy Stinchfield
Jonathan Temte
Greg Wallace**

◆ **Individual immunization
providers**